Johnson & Johnson receives positive CHMP opinion for
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of...
Source: globenewswire.com
Year Survival News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Year Survival. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Year Survival Today - Breaking & Trending Today
Immutep : Corporate Presentation -March 26, 2024 at 08:12 am EDT
Forward-Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 . These slides have been...
Source: marketscreener.com
Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study
The Journal of Lung and Heart Transplantation (JHLT) has published a real-world study indicating a significant reduction in Primary Graft Dysfunction (PGD), a severe post-transplant complication ― potentially allowing for an increase in donor hearts available for heart transplant patients
Source: dicardiology.com
Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer -December 21, 2023 at 08:44 am EST
News Release Media Contacts: Zayn Qureshi +44 7760 334666 Email: zqureshi@its.jnj.com Investor...
Source: marketscreener.com
Dermatology Month in Review: November 2023
The Dermatology Month in Review for dermatology features 2 interviews, findings from recent long-term data, and a discussion of the FDA’s approval of secukinumab for HS.
Source: hcplive.com